NCT05694312View on ClinicalTrials.gov

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 24, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

November 30, 2026

Conditions
Autoimmune Hemolytic AnemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMonoclonal B-Cell Lymphocytosis CLL-Type
Interventions
DRUG

Ibrutinib 420 mg

Patients will receive ibrutinib orally on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of CLL progression or unacceptable toxicity.

Trial Locations (3)

Unknown

RECRUITING

Ematologia Osp Careggi, Florence

RECRUITING

Ematologia Osp Maggiore della Carità, Novara

RECRUITING

Ematologia Osp Molinette, Torino

All Listed Sponsors
lead

Gruppo Italiano Malattie EMatologiche dell'Adulto

OTHER